Find us at Booth 12.
ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company’s pipeline is targeting all key segments of the diabetic eye disease market. ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial to assess THR-409 (ocriplasmin) for inducing total PVD with non proliferative diabetic retinopathy patients. THR-317 is a PIGF inhibitor being developed to treat diabetic macular edema. THR-149 is a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687 is an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered the new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin), now approved for the treatment of vitreomacular traction in 54 countries.
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR.